|
The FDA last week expanded Gilead Sciences’ chronic hepatitis B virus (HBV) drug
Vemlidy’s label to include pediatric patients 12 and older with compensated
liver disease. The drug was first approved in 2016. As of November 2022, 91%
of insured lives have covered or better access to Vemlidy, with 25% of lives
having preferred access to the drug without utilization management
restrictions. |
|
SOURCE: MMIT Analytics,
as of 11/7/22 |
No comments:
Post a Comment